Related Experiment Video

Updated: May 13, 2026

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
08:00

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study

Published on: April 11, 2018

Pathogenesis and management of nasal polyposis in cystic fibrosis

Jochen G Mainz1, Assen Koitschev

  • 1Cystic Fibrosis Center, Department of Paediatrics, Paediatric Pulmonology, Jena University Hospital, Kochstrasse 2,07740 Jena, Germany. jochen.mainz@med.uni-jena.de

Current Allergy and Asthma Reports
|March 23, 2013
PubMed

Insights

Cystic fibrosis (CF) patients often develop nasal polyposis (NP), a condition with unclear causes. Current treatments for CF-NP lack standardization and require more clinical trials for efficacy validation.

Area of Science:

  • Otolaryngology
  • Pulmonology
  • Genetics

Background:

  • Nasal polyposis (NP) affects up to 50% of cystic fibrosis (CF) patients from preschool age.
  • NP is rare in non-CF children, suggesting CF-specific pathogenetic factors.
  • Defective epithelial ion transport and impaired mucociliary clearance in CF contribute to NP development.

Purpose of the Study:

  • To review the current understanding of NP pathogenesis in CF.
  • To discuss existing treatment modalities for CF-NP.
  • To highlight the need for standardized, evidence-based treatment strategies.

Main Methods:

  • Literature review of NP in CF patients.
  • Analysis of pathogenetic mechanisms in CF-related NP.
  • Evaluation of current and proposed therapeutic interventions.

Main Results:

  • Pathogenesis of CF-NP is not fully understood but involves defective ion transport and chronic inflammation.
  • CF-NP is currently not curable, with treatments focusing on clinical stabilization.
  • Existing treatments, including topical steroids and CF-specific therapies, lack standardized protocols and robust clinical trial data.

Conclusions:

  • CF-NP management requires further investigation and evidence-based approaches.
  • Controlled clinical trials are urgently needed to evaluate treatment efficacy.
  • Interdisciplinary collaboration is essential for advancing CF-NP care.

More Related Videos

Culture and Imaging of Human Nasal Epithelial Organoids13:20

Culture and Imaging of Human Nasal Epithelial Organoids

Published on: December 17, 2021

Nasal Potential Difference to Quantify Trans-epithelial Ion Transport in Mice08:55

Nasal Potential Difference to Quantify Trans-epithelial Ion Transport in Mice

Published on: July 4, 2018

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Obstructive Pulmonary Disease-V: Nursing Management01:30

Chronic Obstructive Pulmonary Disease-V: Nursing Management

Nursing management of Chronic Obstructive Pulmonary Disease (COPD) is crucial for providing thorough care and support to patients. Nurses play an integral role in this process through detailed assessment, careful planning, targeted interventions, and ongoing evaluation. Here's an overview of the critical steps in nursing management for COPD.
Assessment